Hemopressin Peptides and WIN Showed Symmetrical Cross-Tolerance After Direct Brain Administration in Mice

A mouse study found antinociceptive tolerance and symmetrical cross-tolerance among hemopressin, VD-hemopressin alpha and WIN55,212-2. The finding applies to direct supraspinal administration and a thermal response, rather than every effect of these ligands.

The ligands carried different pharmacological descriptions

Hemopressin had been characterized as a CB1 antagonist or inverse agonist, while its extended peptide was described as an agonist. Nevertheless, hemopressin produced dose-dependent antinociception after intracerebroventricular administration. A receptor label alone did not settle its observed effect in this protocol.

Repeated exposure reduced the response

Tolerance developed by the fourth treatment day for each of the three ligands. Cross-challenges showed symmetrical cross-tolerance among them on the radiant-heat tail-flick measure. This supports overlap in adaptation under the tested conditions without demonstrating identical molecular actions.

A common mechanism was an inference

The authors interpreted the shared pattern as implying a common antinociceptive mechanism. Cross-tolerance alone cannot specify every receptor interaction or exclude downstream convergence. Nor does symmetry on one thermal endpoint imply symmetry for temperature, movement, reward or other functions.

The study adds an experimentally defined relationship between cannabinoid-related peptides and a synthetic agonist. Direct brain administration and mouse antinociception sharply limit clinical translation. It does not establish oral efficacy, human safety or a method of predicting cannabis impairment.

Related: interpreting cannabis tolerance claims.

Research cited

Pan JX; Wang ZL; Li N; Han ZL; Li XH; Tang HH; Wang P; Zheng T; Fang Q; Wang R. Analgesic tolerance and cross-tolerance to the cannabinoid receptors ligands hemopressin, VD-hemopressin(α) and WIN55,212-2 at the supraspinal level in mice. Neuroscience letters (2014). doi:10.1016/j.neulet.2014.06.058. Findings discussed from the study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

How Did a Laboratory Study Decide That a Detected Drug Was Non-Prescribed?

A laboratory can identify a drug while relying on outside information to classify its prescription status. A national urine-testing study combined analytical results with medication information supplied by the ordering clinician. Two information streams McClure and colleagues analyzed 231,228 test-result sets from 144,535 patients tested for both opioids and benzodiazepines….

Spread the love

Read Article: How Did a Laboratory Study Decide That a Detected Drug Was Non-Prescribed?

How Did a Stress-Management Trial Protocol Handle Medication Changes?

When a study evaluates psychological treatment, medication changes can complicate attribution of improvement. The 2017 Seren@ctif protocol described how investigators planned to address this issue in a trial of adjustment disorder with anxiety. The planned comparison Servant and colleagues proposed three randomized groups receiving computer-based stress management, an equivalent face-to-face…

Spread the love

Read Article: How Did a Stress-Management Trial Protocol Handle Medication Changes?

What Evidence Supports Extending Lipid Rescue to a Different Poison?

A treatment that appears useful for one toxicant raises a separate scientific question when proposed for another. Eisenkraft and Falk’s 2016 review of lipid emulsion and chemical-agent poisoning provides an example of that evidence gap. Several evidence types The authors discussed proposed lipid-scavenging, metabolic, and cardiovascular mechanisms. They reviewed laboratory…

Spread the love

Read Article: What Evidence Supports Extending Lipid Rescue to a Different Poison?

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us